7-溴-2-氯噻吩并[3,2-D]嘧啶 | 1152475-42-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 中文名称: 7-溴-2-氯噻吩并[3,2-D]嘧啶
• 中文别名: 7-溴-2-氯噻吩并[3,2-d]嘧啶；7-溴-2-氯噻吩并3,2-D嘧啶
• 英文名称: 7-bromo-2-chlorothieno[3,2-d]pyrimidine
• CAS: 1152475-42-7
• 化学式: C₆H₂BrClN₂S
• 分子量: 249.518
• InChiKey: OJKRQQNUFWOJAV-UHFFFAOYSA-N

物化性质

• 密度：
  1.955

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Bromo-2-chlorothieno[3,2-d]pyrimidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Bromo-2-chlorothieno[3,2-d]pyrimidine
CAS number: 1152475-42-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H2BrClN2S
Molecular weight: 249.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide, sulfur
oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-溴-2-氯噻吩并[3,2-D]嘧啶 在 bis-triphenylphosphine-palladium(II) chloride sodium carbonate 、 三乙胺 、 2-二-叔丁膦基-2',4',6'-三异丙基联苯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 8.0h， 生成 N-(3-(2-chlorothieno[3,2-d]pyrimidin-7-yl)phenyl)-methanesulfonamide
  参考文献：
  名称：

  2,7-SUBSTITUTED THIENO[3,2-D] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS

  摘要：

  揭示了一种具有蛋白激酶抑制活性的2,7-取代噻吩[3,2-d]嘧啶化合物，以及一种药用可接受的盐和药物组合物，用作预防和治疗由异常细胞生长引起的疾病，包括该化合物作为有效成分。由于这种新型的2,7-取代噻吩[3,2-d]嘧啶化合物对参与生长因子信号传导的各种蛋白激酶表现出卓越的抑制活性，因此它可用作预防或治疗由异常细胞生长引起的疾病的药物。

  公开号：

  US20120277424A1
• 作为产物：
  描述：

  2-氯噻吩并[3,2-d]嘧啶 在 溴 、 过碘酸 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以68.96%的产率得到7-溴-2-氯噻吩并[3,2-D]嘧啶
  参考文献：
  名称：

  [EN] COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH
  [FR] COMPOSÉS QUI MODULENT L'ACTIVITÉ EGFR ET DES PROCÉDÉS POUR TRAITER OU PRÉVENIR DES AFFECTIONS AVEC CEUX-CI

  摘要：

  提供了用于治疗或预防激酶介导的疾病的化合物和方法。

  公开号：

  WO2011079231A1

文献信息

• [EN] N-CONTAINING HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES À TENEUR EN N
  申请人：CYTOPIA RES PTY LTD

  公开号：WO2009062258A1

  公开（公告）日：2009-05-22

  The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

  本发明涉及N-含杂环化合物，其为包括JAK激酶在内的蛋白激酶的抑制剂。特别是，这些化合物对JAK1、JAK2、JAK3或TYK2激酶及其组合物如JAK1和JAK2具有选择性。激酶抑制剂可用于治疗与激酶相关的疾病，如免疫性和炎性疾病，包括器官移植；增生性疾病，包括癌症和骨髓增生性疾病；病毒性疾病；代谢性疾病；以及血管性疾病。
• [EN] HETEROAROMATIC MACROCYCLIC DERIVATIVES AS PROTEIN KINASE INHIBITORS<br/>[FR] DÉRIVÉS MACROCYCLIQUES HÉTÉROAROMATIQUES SERVANT D'INHIBITEURS DE PROTÉINE KINASE
  申请人：KOREA INST SCI & TECH

  公开号：WO2020085742A1

  公开（公告）日：2020-04-30

  The present invention relates to a 2,7-substituted cyano[3,2-d]pyrimidine cyclic compound having protein kinase inhibitory activity, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for preventing, alleviating, or treating a disease caused by abnormal cell growth, which includes the compound as an active ingredient. The novel 2,7-substituted cyano[3,2-d]pyrimidine cyclic compound of the present invention exhibits an excellent effect of inhibiting various protein kinases involved in the signal transduction of growth factors, and thus is effective as an agent for preventing, alleviating, or treating an abnormal cell growth disease caused by these protein kinases.

  本发明涉及一种具有蛋白激酶抑制活性的2,7-取代的氰基[3,2-d]嘧啶环状化合物，其药学上可接受的盐，以及一种包括该化合物作为活性成分的用于预防、缓解或治疗由异常细胞生长引起的疾病的药物组合物。本发明的新型2,7-取代的氰基[3,2-d]嘧啶环状化合物表现出优异的抑制与生长因子信号转导相关的各种蛋白激酶的效果，因此作为一种药剂对由这些蛋白激酶引起的异常细胞生长疾病的预防、缓解或治疗是有效的。
• 단백질 키나아제 저해제인 헤테로방향족 매크로시클릭 유도체
  申请人：KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY 한국과학기술연구원(319980077518) BRN ▼209-82-03522

  公开号：KR20200046952A

  公开（公告）日：2020-05-07

  본 발명은 단백질 키나아제 저해활성을 갖는 2,7-치환된 사이아노[3,2-d]피리미딘 고리화된 화합물, 이의 약학적으로 허용 가능한 염, 그리고 이 화합물을 유효성분으로 함유하는 비정상 세포 성장으로 유발되는 질환의 예방, 경감 또는 치료용 약학적 조성물에 관한 것이며, 본 발명의 신규 2,7-치환된 사이아노[3,2-d]피리미딘 고리화된 화합물은 성장 인자 신호 전달에 관여하는 다양한 단백질 키나아제에 대하여 우수한 억제 효과를 나타내므로, 이들 단백질 키나아제에 의해 유발되는 비정상 세포 성장 질환의 예방, 경감 또는 치료제로서 유용하다.

  这项发明涉及具有蛋白激酶抑制活性的2,7-取代的环氰[3,2-d]嘧啶化合物，其药学上可接受的盐，以及含有该化合物作为有效成分的用于预防、减轻或治疗由异常细胞生长引起的疾病的药学组合物。这些新型的2,7-取代的环氰[3,2-d]嘧啶化合物表现出对涉及生长因子信号传导的多种蛋白激酶具有优越的抑制作用，因此对由这些蛋白激酶引起的异常细胞生长疾病的预防、减轻或治疗具有用处。
• FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF
  申请人：GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.

  公开号：US20180208604A1

  公开（公告）日：2018-07-26

  Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

  揭示的区域融合环嘧啶化合物，以及中间体、制备方法、组合物及其用途。融合环嘧啶化合物是如下式I所示的化合物，其为互变异构体、对映异构体、顺反异构体、药学上可接受的盐、代谢物、代谢前体或其前药，上述化合物用于制备用于预防、缓解或治疗免疫系统疾病、自身免疫疾病、细胞增殖性疾病、过敏性疾病和心血管疾病中的一种或多种的药物，且该化合物对Janues激酶、FGFR激酶、FLT3激酶和Src家族激酶具有强烈的抑制作用。
• Identification of Thieno[3,2-<i>d</i>]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3
  作者：Hanna Cho、Injae Shin、Hojong Yoon、Eunhye Jeon、Jiwon Lee、Younghoon Kim、SeongShick Ryu、Chiman Song、Nam Hoon Kwon、Youngji Moon、Sunghoon Kim、Nam Doo Kim、Hwan Geun Choi、Taebo Sim

  DOI：10.1021/acs.jmedchem.1c00459

  日期：2021.8.26

  Focal adhesion kinase (FAK) is overexpressed in highly invasive and metastatic cancers. To identify novel FAK inhibitors, we designed and synthesized various thieno[3,2-d]pyrimidine derivatives. An intensive structure–activity relationship (SAR) study led to the identification of 26 as a lead. Moreover, 26, a multitargeted kinase inhibitor, possesses excellent potencies against FLT3 mutants as well

  粘着斑激酶 (FAK) 在高度侵袭性和转移性癌症中过度表达。为了鉴定新型 FAK 抑制剂，我们设计并合成了各种噻吩并[3,2- d ]嘧啶衍生物。一项深入的构效关系 (SAR) 研究确定了26 个先导化合物。此外， 26是一种多靶点激酶抑制剂，对 FLT3 突变体和 FAK 具有优异的功效。令人欣喜的是， 26显着抑制顽固的 FLT3 突变体，包括导致耐药性的 F691L。重要的是，在 MDA-MB-231 异种移植小鼠模型中， 26在细胞凋亡诱导、锚定非依赖性生长抑制和肿瘤负荷减轻方面优于 PF-562271。此外， 26还能使 MV4-11 异种移植小鼠模型中的肿瘤生长消退，表明它可以有效对抗急性髓系白血病 (AML)。最后，在使用 MDA-MB-231 的原位小鼠模型中， 26显着阻止了原位肿瘤向淋巴结的转移。总而言之，结果表明26对高侵袭性癌症和复发性 AML 具有潜在的治疗价值。